According to FMI’s most recent market research, the global microneedle drug delivery systems market is projected to grow at a compound annual growth rate (CAGR) of 6.6% between 2023 and 2033. The market is expected to grow to a valuation of US$ 768.9 million by 2023. It is projected that the valuation will reach US$.
SK Bioscience Co. Ltd. and Vaxxas Pty. Ltd. have entered into a joint development agreement that could revolutionize vaccines by developing a vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) coupled with SK Bioscience’s typhoid vaccine, Skytyphoid.
[238 Pages Report] Emerging applications of microneedle drug delivery systems are expected to fuel their demand over the next decade. According to a recent report published by Future Market Insights (FMI), the global microneedle drug delivery systems market will grow at a CAGR of 6.6% between 2020 and 2030. The mark.